Genta
Executive Summary
Enters a collaboration with Mountain View, Calif.-based CV Therapeutics to develop "anticode" drugs for the treatment and prevention of restenosis following coronary angioplasty and for other vascular applications, San Diego biotech firm announces April 12. Genta gains co-ownership with CV of a worldwide license to "certain antisense technology" developed at Stanford for vascular conditions, Genta says.